Despite lower rates of pCR in HER2-positive/HR-positive tumours, it has been reported that these tumours have a good prognosis, and that there is thus a weaker association between pCR and long-term outcome in HER2-positive/HR-positive tumours than HER2-positive/HR-negative tumours [8, 35]. This evidence concerns the gene ERBB2 and neoplasm.